MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD9 Codes        Equipment        Hospitals        Drugs        More..
  

Useful Websites

Global Translations
Medical and Clinical Translation

specialistinfo.com
Details of over 40,000 UK Specialists and over 42,000 GPs

Global RPH
medical software

Doctors Lounge
Ask a Doctor and Disease Information

Health News
from Medical News Today.

MRCP 1 Revision
123 Doc medical courses for junior doctors.

CoreyNahman
pharmaceutical news daily

Hospital Search
Worldwide hospital database, search by country or keyword.

Metric Conversions
The Converter Site - unit conversion tool.
home > drug information > Moxatag

Moxatag (amoxicillin)


Company: MiddleBrooke Pharmaceuticals
Approval Status: Approved January 2008
Treatment for: tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatrics
Areas: Immunology/Infectious Diseases; Otolaryngology; Pediatrics/Neonatology

| General Information | Clinical Results | Side Effects | Mechanism of Action | Literature References | Additional Information |


General Information

Other Useful Resources

Moxatag contains amoxicillin, a semi-synthetic antimicrobial belonging to the penicillin class of antimicrobials with activity against gram-positive and gram-negative bacteria. Moxatag is an extended release tablet formulation consisting of three components, one immediate-release and two delayed-release, each containing amoxicillin. The three components are combined in a specific ratio to prolong the release of amoxicillin from Moxatag compared to immediate-release amoxicillin.

Moxatag is specifically indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes (S. pyogenes) in adults and pediatric patients 12 yrs and older.

Moxatag is supplied as a 775 mg tablet designed for oral administration. The recommended initial dose of the drug is 775 mg once daily taken within 1 hour of finishing a meal for 10 days. The full 10-day course of therapy should be completed for effective treatment of tonsillitis and/or pharyngitis secondary to S. pyogenes. Moxatag is contraindicated in patients with known serious hypersensitivity to amoxicillin or to other drugs in the same class or patients who have demonstrated anaphylactic reactions to beta-lactams.



< back to top

Clinical Results

FDA Approval
FDA approval of Moxatag was based on the results of a clinical trial. This randomized, parallel-group, multi-center, double-blind, double-dummy study enrolled adult and pediatric subjects, aged 12 years and older, with tonsillitis and/or pharyngitis secondary to S. pyogenes. The subjects received Moxatag 775 mg QD or penicillin VK 250 mg QID, both for 10 days. Moxatag was determined to be non-inferior to penicillin. The results were as follows:

Modified intent-to-treat population
This included all randomized subjects with a positive throat culture for S. pyogenes at baseline. Bacterial eradication was observed in 79.7% of the Moxatag arm and 78% in the penicillin arm.
Per-protocol population
This included mITT subjects who had post-therapy cultures, were compliant with treatment, and didn’t have major protocol violations. Bacterial eradication was observed in 85% of the Moxatag arm and 83.4% of the penicillin arm.

Ongoing Study Commitments

  • MiddleBrooke Pharma has agreed to conduct a pediatric study of an amoxicillin extended-release formulation for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in pediatric patients two to less than 12 years of age.
    Final Report Submission: March 31, 2013

< back to top

Side Effects

Adverse events associated with the use of Moxatag may include, but are not limited to, the following:

  • Vulvovaginal mycotic infection
  • Diarrhea
  • Nausea
  • Vomiting
  • Headache
  • Abdominal pain

< back to top

Mechanism of Action

Moxatag contains amoxicillin, a semi-synthetic antimicrobial belonging to the penicillin class of antimicrobials with activity against gram-positive and gram-negative bacteria. Moxatag is an extended release tablet formulation consisting of three components, one immediate-release and two delayed-release, each containing amoxicillin. The three components are combined in a specific ratio to prolong the release of amoxicillin from Moxatag compared to immediate-release amoxicillin. Amoxicillin exerts its bactericidal action against susceptible organisms during the stage of multiplication. It acts through the inhibition of biosynthesis of cell wall mucopeptide. To date there are no known mechanisms of resistance to penicillin or amoxicillin in Streptococcus pyogenes.



< back to top

Literature References

Clegg HW, Ryan AG, Dallas SD, Kaplan EL, Johnson DR, Norton HJ, Roddey OF, Martin ES, Swetenburg RL, Koonce EW, Felkner MM, Giftos PM Treatment of streptococcal pharyngitis with once-daily compared with twice-daily amoxicillin: a noninferiority trial. The Pediatric Infectious Disease Journal 2006 Sep;25(9):761-7

Aguilar A, Tinoco JC, Macias M, Huicho L, Levy J, Trujillo H, Lopez P, Pereira M, Maqbool S, Bhutta ZA, Sacy RA, Deacon S Clinical and bacteriologic efficacy of amoxycillin b.d. (45 mg/kg/day) versus amoxycillin t.d.s (40 mg/kg/day) in children with group A beta-hemolytic streptococcal tonsillopharyngitis. Journal of Chemotherapy 2000 Oct;12(5):396-405

Cohen R, Levy C, Doit C, De La Rocque F, Boucherat M, Fitoussi F, Langue J, Bingen E Six-day amoxicillin vs. ten-day penicillin V therapy for group A streptococcal tonsillopharyngitis. The Pediatric Infectious Disease Journal 1996 Aug;15(8):678-82



< back to top

Additional Information

For additional information regarding Moxatag or tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes, please visit the Moxatag web page.



< back to top



The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.




free web search box


pda medical dictionary
pda software - $15

PDA Medical Dictionary

only $15

Take MediLexicon's abbreviations search with you where-ever you go with our PDA software. As an extra, this software is available with an extra medical dictionary...

>> Click here for more on the PDA Medical Dictionary <<




add to google

Add our searches to your Google homepage.

Add to Google

The 60 seconds challenge: Add these searches to your Google homepage within 60 seconds - simply click here and follow these instructions


Receive the latest medical news on your Google homepage.

Add to Google

The 60 seconds challenge: Receive the latest medical news on your Google homepage within 60 seconds - simply click here and follow these instructions





Privacy Policy   |    Disclaimer      

MediLexicon International Ltd, UK Office: +44 (0) 1625 415 347
MediLexicon International Ltd © 2009 All rights reserved.